Medikamentöse Therapie in der Primärsituation des high-grade serösen Ovarialkarzinoms

In recent years, the treatment of primary advanced ovarian cancer has been significantly improved by the incorporation of PARP inhibitors into the therapeutic regimen. Complementing the Olaparib approval for BRCA-positive patients, niraparib is available in the first-line setting regardless of BRCA mutation status. For BRCA-positive patients and patients with evidence of homologous recombination deficiency (HRD), combined maintenance therapy with Olaparib and bevacizumab is available. The current AGO-Ovar 28 trial will address the question of whether maintenance therapy with a PARP inhibitor alone is sufficient as a standard option, or whether the addition of bevacizumab is required for patient benefit.